GU

Guardian Bio

YC S22

Boston, US · Founded 2022 · 2 employees · 1 known investors

guardian-bio.com ↗

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

Founders & leadership· Y Combinator alumni (S22)

AZ

Ananya ZutshiinFounder

RB

Ricky BarrettinFounder

DP

Dr. PaluckaAcademic Co-Founder, Chair, Scientific Advisory Board

Investors · 1

Y

Y CombinatorSan Francisco · $500K